Special Issue “Novel Approaches to Potential COVID-19 Molecular Therapeutics”
International Journal of Molecular Sciences · 07.06.2026 · 27 (12) · 5170
DOI: 10.3390/ijms27125170 ↗Kurz gefasst
Editorial in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 07.06.2026. Verfasst von Monica Gelzo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli Federico II, 80131 Naples, Italy. Hauptthemen laut MEDLINE: Antiviral Agents. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Several years after its emergence, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [...]
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli Federico II, 80131 Naples, Italy.
- CEINGE-Biotecnologie Avanzate Franco Salvatore, 80131 Naples, Italy.
- Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli Federico II, 80131 Naples, Italy.
ORCID-Profile: Monica Gelzo, Felice Amato, Ivan Gentile
Zitieren
APA
Gelzo, M., Amato, F., Gentile, I., & Castaldo, G. (2026). Special Issue “Novel Approaches to Potential COVID-19 Molecular Therapeutics”. International Journal of Molecular Sciences, 27(12), 5170. https://doi.org/10.3390/ijms27125170
Vancouver
Gelzo M, Amato F, Gentile I, Castaldo G. Special Issue “Novel Approaches to Potential COVID-19 Molecular Therapeutics”. International Journal of Molecular Sciences. 2026;27(12):5170. doi:10.3390/ijms27125170
BibTeX
@article{Gelzo2026,
author = {Gelzo, Monica and Amato, Felice and Gentile, Ivan and Castaldo, Giuseppe},
title = {Special Issue “Novel Approaches to Potential COVID-19 Molecular Therapeutics”},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {12},
pages = {5170},
doi = {10.3390/ijms27125170}
}
EUVIMED